- Home
- HPE vs BIIB Comparison
HPE vs BIIB Comparison
Compare HPE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPE | BIIB |
|---|---|---|
| Founded | 1939 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 24.2B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | HPE | BIIB |
|---|---|---|
| Price | $23.94 | $175.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | $26.13 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 29.1M | 2.0M |
| Earning Date | 12-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.97 |
| Revenue | ★ $34,296,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $20.01 | $3.61 |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | $15.86 |
| Revenue Growth | ★ 13.84 | 4.77 |
| 52 Week Low | $11.97 | $110.04 |
| 52 Week High | $26.44 | $185.17 |
Technical Indicators
Market Signals| Indicator | HPE | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 56.69 |
| Support Level | $23.69 | $169.24 |
| Resistance Level | $25.41 | $180.79 |
| Average True Range (ATR) | 0.85 | 5.04 |
| MACD | 0.30 | -1.57 |
| Stochastic Oscillator | 70.00 | 42.85 |
Price Performance
Historical ComparisonAbout HPE Hewlett Packard Enterprise Company
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).